On June 23, the United States Court of Appeals for the Federal Circuit affirmed in favor of numerous generic pharmaceutical companies in a patent case against Pfizer. At issue was one of the key patents protecting Pfizer’s drug Celebrex® from generic competition. Taft represented Apotex Inc., one of the largest generic pharmaceutical manufacturers in the world. Read the decision here.